NCT02514083 A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02507479 Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Status UNKNOWN Phase PHASE2
NCT02506933 Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02491398 Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia Status COMPLETED Phase N/A
NCT02481297 Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients Status COMPLETED Phase PHASE2
NCT02477696 Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02475681 Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02456350 Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies Status UNKNOWN Phase PHASE1
NCT02440685 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT02427451 Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02424968 CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma Status COMPLETED Phase PHASE2
NCT02396134 Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Status COMPLETED Phase PHASE2
NCT02340780 Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia Status COMPLETED Phase PHASE2
NCT02339922 Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02337829 Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Status COMPLETED Phase PHASE2
NCT02320487 A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Status COMPLETED Phase PHASE2
NCT02316197 Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia Status COMPLETED Phase PHASE1